Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo.
Retinoids have been successfully used in the treatment of some forms of leukaemia, suggesting that such cells have an efficient uptake mechanism for circulating retinoids. Therefore, we have studied the uptake of lipoprotein-associated retinyl esters in human leukocytes in vivo. After an oral load of 100 mumol retinyl palmitate (30,000 retinol equivalents) per square meter given to healthy adults, the concentration of retinoids in circulating leukocytes was determined. A peak was measured after 5 h, which coincided with a peak of retinyl esters in plasma. To test whether low-density lipoprotein receptors are necessary for the postprandial uptake of retinoids, we studied retinoid uptake in leukocytes from two patients homozygous for familial hypercholesterolaemia. After an oral load of retinoids we found that leukocytes from these patients took up at least as much retinoid as leukocytes in normal individuals, suggesting that uptake of chylomicron remnant retinyl esters may proceed independent of the low-density lipoprotein receptor. The expression of mRNA for the low density lipoprotein receptor-related protein, which is a putative chylomicron remnant receptor, was similar in leukocytes from a patient homozygous for familial hypercholesterolaemia and normal individuals. Six hours after vitamin A administration, recovery of unesterified retinol was 71% in normal leukocytes, however, only 9% unesterified retinol was recovered in leukocytes from the two patients with familial hypercholesterolaemia. Thus, the apparent rate of retinyl ester hydrolysis was markedly reduced in leukocytes from these patients, indicating different intracellular traffic of chylomicron remnants in normal individuals and patients homozygous for familial hypercholesterolaemia.
Skrede
B
B
Institute for Nutrition Research, School of Medicine, University of Oslo, Norway.
Blomhoff
R
R
Maelandsmo
G M
GM
Ose
L
L
Myklebost
O
O
Norum
K R
KR
D001693:Biological Transport, Active; D002914:Chylomicrons / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D006868:Hydrolysis; D006938:Hyperlipoproteinemia Type II / Q000097:blood; D007700:Kinetics; D007962:Leukocytes / Q000378:metabolism*; D012333:RNA, Messenger / Q000097:blood; D011973:Receptors, LDL / Q000378:metabolism; D012176:Retinoids / Q000097:blood / Q000493:pharmacokinetics*; D014801:Vitamin A / Q000097:blood / Q000493:pharmacokinetics
D002914:Chylomicrons; D012333:RNA, Messenger; D011973:Receptors, LDL; D012176:Retinoids; D014801:Vitamin A